Cytodyn Inc (CYDY)

[finesand]

Pro 140 Related Publications (update)

Opinion

Science is genuine, Pro 140 found before 1999 and is well covered in the scientific community via peer reviewed papers - undisputed.

Safety profile is extraordinary, especially since Pro 140 does not impact CCR5 host receptor normal operations.

2017's CROI poster's data also demonstrated how well Pro 140 does scale with dosage and frequency of administration.
The Viral Load suppression curve matches its method of action.

No detected Pro 140 antibodies in any patient.

Efficacy on CCR5-tropic HIV-1 has been proven since 2010 and we are looking forward to the latest trial data,
a paper before June's ASM and/or the poster at June's ASM the latest.

Publications

https://www.sciencedirect.com/search/advanced?qs=Pro%20140&show=25&sortBy=relevance

https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=%22PRO+140%22&scisbd=1 (date)
https://scholar.google.com/scholar?hl=en&as_sdt=0,5&q=%22PRO+140%22 (relevance)

2018.04 The return of PRO 140, a CCR5-directed mAb. 
         https://www.ncbi.nlm.nih.gov/pubmed/29708899 
         https://insights.ovid.com/crossref?an=01222929-900000000-99306 
         MISSING 
  
 2018.04 PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, 
         single-agent maintenance therapy for HIV-1 infection 
         https://www.tandfonline.com/doi/abs/10.1080/15284336.2018.1452842?journalCode=yhct20 
         https://cdn.discordapp.com/attachments/282295630796161024/448148726909763594/PRO_140_a_monoclonal_antibody_targeting_CCR5_as_a_long_acting_single_agent_maintenance_therapy_for_H.pdf 
  
 2018.03 Engineering therapeutic antibodies to combat infectious diseases 
         https://www.sciencedirect.com/science/article/pii/S2211339817300497 
         https://cdn.discordapp.com/attachments/282295630796161024/437980669063462922/1-s2.0-S2211339817300497-main.pdf 
  
 2018.01 Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir 
         https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01337 
         https://cdn.discordapp.com/attachments/282295630796161024/448072192463208458/Fostemsavir.acs.jmedchem.7b01337.pdf 
  
 2017.09 New Drugs in the Pipeline for the Treatment of HIV: a Review 
         https://link.springer.com/article/10.1007%2Fs11908-017-0601-x 
         https://cdn.discordapp.com/attachments/282295630796161024/437980517044846607/10.10072Fs11908-017-0601-x.pdf 
  
 2017.06 ASM Microbe '17 Poster: Interim Results in a Phase 2b/3 Pivotal Study of PRO 140 
                         in Treatment Experienced HIV-1 Patients with Multiple ARV Class Resistance 
         https://content.equisolve.net/cytodyn/media/f800c6057fab55bfa6e3e5fdca0958b2.pdf 
         https://cdn.discordapp.com/attachments/282295630796161024/437980570845315072/ASM_Microbe.pdf 
  
 2017.02 CROI '17 Poster: PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update 
         https://content.equisolve.net/cytodyn/media/506e06db35c45e222df77b15e7b5fc98.pdf 
         https://cdn.discordapp.com/attachments/282295630796161024/437980587941298197/CROI_Poster_Presentation.pdf 
  
 2014.02 CCR5 Plays Important Roles in Hepatitis B Infection 
         online.liebertpub.com/doi/abs/10.1089/vim.2013.0067#/doi/abs/10.1089/vim.2013.0067 
         https://cdn.discordapp.com/attachments/282295630796161024/448148680592195605/CCR5_Plays_Important_Roles_in_.pdf 
  
 2011.03 The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy 
         https://link.springer.com/article/10.1007%2Fs11904-010-0068-y 
         https://cdn.discordapp.com/attachments/282295630796161024/448148736837812234/The_Monoclonal_CCR5_Antibody_PRO-140_The_Promise.pdf 
  
 2010.07 Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults 
         http://aac.asm.org/content/54/10/4137.short 
         http://aac.asm.org/content/54/10/4137.full 
         https://cdn.discordapp.com/attachments/282295630796161024/448148700947021836/Phase_2a_Study_of_the_CCR5_Monoclonal_Antibody_PRO_140.pdf 
  
 2010.05 Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody 
         https://academic.oup.com/jid/article/201/10/1481/992206 (free) 
         https://www.ncbi.nlm.nih.gov/pubmed/20377413?dopt=Abstract 
         https://cdn.discordapp.com/attachments/282295630796161024/448148624392585236/Anti-HIV-1_Activity_of_Weekly_or_Biweekly_.pdf 
  
 2010.03 PRO 140 (a CCR5 monoclonal antibody) for treatment in people with HIV infection 
         http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD008439/full 
         https://cdn.discordapp.com/attachments/282295630796161024/437980651174756353/Li_et_al-2010-.pdf 
  
 2009.10 Review Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc 
         http://insights.sagepub.com/redirect_file.php?fileId=2397&filename=1701-CMT-Pharmacotherapy-of-HIV-1-Infection:-Focus-on-CCR5-Antagonist-Maraviroc.pdf&fileType=pdf 
         https://cdn.discordapp.com/attachments/282295630796161024/437980634485489673/f_1701-CMT-Pharmacotherapy-of-HIV-1-Infection-Focus-on-CCR5-Antagonist-Maraviroc.pdf_2397.pdf 
  
 2008.11 Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults 
         https://academic.oup.com/jid/article/198/9/1345/834086 (free) 
         https://cdn.discordapp.com/attachments/282295630796161024/448148657997611038/Antiviral_Activity_of_Single-Dose_PRO_140_a_CCR5_.pdf 
  
 2006.06 Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1 
         http://aac.asm.org/content/50/10/3289.abstract?sid=f07d13da-4174-4f2e-b7bc-8d203d0b808d 
         https://cdn.discordapp.com/attachments/282295630796161024/448148636203876355/Antimicrob._Agents_Chemother.-2006-Murga-3289-96.pdf 
  
 2000.10 Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 
         http://jvi.asm.org/content/75/2/579.short 
         http://jvi.asm.org/content/75/2/579.abstract?site=JVirol&utm_source=TrendMDJVirol&utm_medium=TrendMDJVirol&utm_campaign=trendmdalljournals_0 
         https://cdn.discordapp.com/attachments/282295630796161024/448148713312092170/Potent_Broad-Spectrum_Inhibition_of_Human_.pdf